Prognose
| Køb |
6 |
| Behold |
5 |
| Sælg |
2 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Spero Therapeutics receives $105 million from KKR unit, stock falls
Spero Therapeutics entered into a $105 million licensing and financing agreement with subsidiaries of Healthcare Royalty (KKR). HCRx will receive a portion of milestone and royalty payments from GSK’s Utebzi sales and will receive quarterly principal and interest payments from those receipts; after full repayment Spero will retain 35% of subsequent GSK payments. The funds will be used primarily to advance the phase-2 immunology candidate SP001, and Spero’s cash runway has been extended into the second half of 2029. The announcement pushed Spero’s stock down about 12% in premarket trading. » Mere på de.investing.com
Spero Therapeutics secures $105 million financing from KKR unit for SP001 development
Spero Therapeutics agreed a non‑recourse royalty financing of $105 million with Healthcare Royalty (KKR), assigning part of future milestone and license payments from Utebzi sales. The funds will finance development of SP001, a monoclonal anti‑CD40L antibody intended for Phase 2; simultaneously Spero signed an exclusive licensing agreement with Innovent for SP001. Healthcare Royalty will receive quarterly principal and interest payments from GSK payments, and after repayment Spero will retain 35% of subsequent GSK payments; Spero thereby extends its cash runway into the second half of 2029 and reports a current ratio of 10.5. » Mere på de.investing.com
Spero Therapeutics rises 16% after FDA approval for Utebzi
Shares of Spero Therapeutics climbed 16% after the FDA approved Utebzi, an oral carbapenem developed with GSK to treat complicated urinary tract infections in adults with limited oral options. Utebzi is the first oral carbapenem approved in the U.S.; the approval is based on the Phase III PIVOT-PO study, which showed noninferiority to intravenous imipenem‑cilastatin. The drug is expected to be available in the U.S. by the end of 2026; development was partially supported by BARDA. » Mere på de.investing.com
Spero Therapeutics: board member Mahadevia resigns, SEC ends investigation
Dr. Ankit Mahadevia has resigned from the board of Spero Therapeutics with immediate effect and has also relinquished his committee and subsidiary mandates; the company cites other professional commitments for the resignation. Spero plans to engage Mahadevia as a consultant to continue supporting management. The U.S. securities regulator SEC said that, based on available information, it currently does not intend to pursue enforcement actions against Spero. In addition, the FDA’s re‑filing of the NDA for the oral carbapenem tebipenem HBr triggers an expected $25 million milestone payment to Spero in Q1 2026, subject to acceptance of the filing. » Mere på de.investing.com
Spero Therapeutics beats Q2 expectations and stock rises
Spero Therapeutics reported Q2 2025 EPS of -$0.03 on revenue of $14.2 million, both well above expectations, and the stock rose double‑digit after the results. The company sharply reduced its net loss, extended its financing runway to 2028, and views Tebipenem HBr—after a successful Phase‑3 study—as on track for possible FDA approval in 2026. Challenges remain in the SPR720 program, and dependence on milestone payments continues to be a risk. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalI 2015 har SPERO THERAP.INC. DL-,001 allerede udloddet 0,0534 € i udbytte. Den seneste udlodning fandt sted i oktober 2015.
Virksomhedstal
I det seneste kvartal havde SPERO THERAP.INC. DL-,001 en omsætning på 0 € og et nettoresultat på -39,09 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 0 | 100,00 % |
| Bruttofortjeneste | 0 | 100,00 % |
| Nettoresultat | -39,09 mio. | 521,43 % |
| EBITDA | -6,1 mio. | 2,27 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 46,41 mio. € |
Antal aktier | 58,26 mio. |
Højeste/laveste i 52 uger | 2,81 € - 0,79 € |
| Udbytte | Nej |
Beta | 1,56 |
P/E (PE Ratio) | -1,78 |
PEG (PEG Ratio) | 0,00 |
K/I (PB Ratio) | 65,16 |
P/S (PS Ratio) | 1,28 |
Virksomhedsprofil
Spero Therapeutics, Inc., et klinisk fase biofarmaceutisk selskab, fokuserer på at identificere, udvikle og kommercialisere behandlinger mod multiresistente (MDR) bakterielle infektioner og sjældne sygdomme i USA. Selskabets produktkandidater omfatter tebipenempivoxilhydrobromid (HBr), et oralt antibiotikum i carbapenem-klassen til behandling af komplicerede urinvejsinfektioner, herunder pyelonefritis hos voksne; SPR206, et direkte virkende, intravenøst administreret middel til behandling af MDR Gram-negative bakterielle infektioner på hospitaler; og SPR720, et oralt antibiotikum til behandling af ikke-tuberkuløs mykobakteriel lungesygdom. Selskabet har en licensaftale med Meiji Seika Pharma Co., Ltd. om at støtte udviklingen af tebipenem HBr; en licensaftale med Everest Medicines om at udvikle, fremstille og kommercialisere SPR206 i Greater China, Sydkorea og Sydøstasiatiske lande; en samarbejdsaftale med Bill & Melinda Gates Medical Research Institute om at udvikle SPR720 til behandling af lungeinfektioner forårsaget af Mycobacterium tuberculosis; og en licensaftale med Vertex Pharmaceuticals Incorporated vedrørende patenter relateret til SPR720 samt SPR719, et aktivt metabolit. Selskabet blev grundlagt i 2013 og har hovedkvarter i Cambridge, Massachusetts.
| Navn | SPERO THERAP.INC. DL-,001 |
| CEO | Esther Rajavelu |
| Hjemsted | Cambridge,
ma USA |
| Websted | |
| Sektor | Materialer |
| Branche | Kemikalier |
| Børsnotering | 02.11.2017 |
| Medarbejdere | 25 |
Deep Dive
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | SPRO |
Frankfurt | 2HA.F |
Düsseldorf | 2HA.DU |
München | 2HA.MU |